{"nctId":"NCT02595970","briefTitle":"Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis","startDateStruct":{"date":"2015-05-20","type":"ACTUAL"},"conditions":["Psoriasis"],"count":120,"armGroups":[{"label":"Secukinumab","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab"]}],"interventions":[{"name":"Secukinumab","otherNames":["open label, no other intervention"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patients with a history of chronic, moderate to severe plaque psoriasis (PASI ≥12; BSA (body surface area) ≥10 and IGA mod 2011 (Investigator's Global Assessment) ≥3) for at least 6 months\n* patient candidates for systemic therapy.\n* informed consent.\n\nExclusion Criteria:\n\n* previous treatment with agent targeting IL-17 (interleukine-17) or IL-17 receptor.\n* recent treatment with topical treatment (2 weeks), systemic agents (4 weeks for methotrexate, Ciclosporine A; systemic retinoids and other systemic treatment), TNF (tumor necrosis factor) inhibitors (3 months) or IL-12/23 inhibitors (6 months).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"proSPI (s) at Week 16 Compared to Baseline","description":"The primary efficacy outcome of this study evaluates the benefit of secukinumab on the severity of psoriasis based on the SPI. This index comprises 3 components: severity (SPIs), psychosocial (SPIp) and intervention (SPIi) and were evaluated by both health care professional (professional, proSPI) and the patient (self-administered: saSPI). Only the severity components were evaluated for the primary objective: proSPI (s) and saSPI (s). Changes at Week 16 compared to Baseline in patients suffering from moderate to severe plaque psoriasis were analyzed for the purpose of this study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.89","spread":"10.747"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"6.144"}]}]}]},{"type":"SECONDARY","title":"PASI (Psoriasis Area Severity Index) Score","description":"PASI administered by a professional score range: 0 (no disease) to 72 (maximal disease)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.09","spread":"10.541"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":"3.927"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.16","spread":"5.427"}]}]}]},{"type":"SECONDARY","title":"Correlation Between PASI and proSPI (s)","description":"Psoriasis Area Severity Index vs Professional Version of Simplified Psoraisis Index (proSPI) score","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.691","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.814","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.927","spread":null}]}]}]},{"type":"SECONDARY","title":"proSPI (s, p and i) Over Time","description":"Professional Version of Simplified Psoriasis Index (proSPI)\n\nSPI for Simplified Psoriasis Index. SPI is composed of 3 domains :\n\n* s for the severity, min =0 and max=50\n* p for the psychosocial, min=0 and max=10\n* i for the intervention, min = 0 and max = 10 For each domain, high values represented a worse outcome The 3 subscales cannot be combined Please use sore on a scale for the unit of measure","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.89","spread":"10.747"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.83","spread":"4.427"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":"6.557"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.80","spread":"1.885"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"2.201"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.59","spread":"2.341"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.26","spread":"1.924"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.78","spread":"1.633"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.67","spread":"1.613"}]}]}]},{"type":"SECONDARY","title":"saSPI (s, p and i) Over Time","description":"Self-administered Simplified Psoriasis Index (saSPI)\n\nSPI for Simplified Psoriasis Index. SPI is composed of 3 domains :\n\n* s for the severity, min =0 and max=50\n* p for the psychosocial, min=0 and max=10\n* i for the intervention, min = 0 and max = 10 For each domain, high values represented a worse outcome The 3 subscales cannot be combined Please use sore on a scale for the unit of measure","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.54","spread":"10.412"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":"4.319"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":"4.229"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.18","spread":"1.855"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":"2.299"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":"2.126"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.34","spread":"1.940"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.39","spread":"2.221"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.33","spread":"2.276"}]}]}]},{"type":"SECONDARY","title":"DLQI (Dermatology Life Quality Index) Over Time","description":"DLQI score has a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired\n\nMEANING OF DLQI SCORES 0 - 1 no effect on patient's life 2 - 5 small effect on patient's life 6 - 10 moderate effect on patient's life 11 - 20 very large effect on patient's life 21 - 30 extremely large effect on patient's life","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":"7.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"3.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"3.37"}]}]}]},{"type":"SECONDARY","title":"Self-administered PASI (SA-PASI)","description":"self-administered PASI (SA-PASI) score","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":"13.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"6.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"7.10"}]}]}]},{"type":"SECONDARY","title":"Psoriasis Symptom Diary (PSD) Score","description":"assessment of pain, itching and scaling using the Psoriasis Symptom Diary questionnaire over time\n\nPSD scores range from 0 to 10, with higher scores indicating a worse condition for each assessment: pain, itching and scaling","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"3.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"2.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"2.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"2.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"2.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"2.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"2.00"}]}]}]},{"type":"SECONDARY","title":"Correlation Between proSPI (for Each Component: s, p and i) and DLQI","description":"Correlation between proSPI (for each component: s, p and i) and DLQI is summarized in table below","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.224","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.418","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.514","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.494","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.671","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.757","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.016","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.131","spread":null}]}]}]},{"type":"SECONDARY","title":"Correlation Between proSPI (for Components p and i) and PASI","description":"Correlation between proSPI (p, i) and PASI score by visit (Full Analysis Set (observed)) is summarized in table below","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.678","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.749","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.014","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.172","spread":null}]}]}]},{"type":"PRIMARY","title":"Changes of saSPI (s) at Week 16 Compared to Baseline","description":"The primary efficacy objective of the study was to evaluate the benefit of secukinumab on the severity of psoriasis based on the SPI. This index comprises 3 components: severity (SPIs), psychosocial (SPIp) and intervention (SPIi) and were evaluated by both health care professional (professional, proSPI) and the patient (self-administered: saSPI). Only the severity components were evaluated for the primary objective: proSPI (s) and saSPI (s). Changes at Week 16 compared to Baseline in patients suffering from moderate to severe plaque psoriasis were analyzed. proSPI (s) score range is 0 to 50. Higher score means worse condition","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.54","spread":"10.412"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":"4.508"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":120},"commonTop":["Nasopharyngitis","Back pain","Diarrhoea","Bronchitis","Rhinitis"]}}}